SAFUSIDENIB (AB-218) FOR IDH1 MUTANT GLIOMA
A Phase 2 randomized open-label trial to evaluate safety and efficacy of Safusidenib (AB-218) in patients with recurrent or progressive IDH1 mutant Glioma.
Talk to an Ivy Navigator
602-406-8605Talk to an Ivy Navigator
602-406-8605A Phase 2 randomized open-label trial to evaluate safety and efficacy of Safusidenib (AB-218) in patients with recurrent or progressive IDH1 mutant Glioma.